NEW YORK (TheStreet.com) -- CHANGE IN RATINGS
Altra (AIMC) - Get Report upgraded at Merrill/BofA to Buy from Neutral as Altra's valuation doesn't reflect an improved cost structure. Price target boosted to $13 from $6. 2009 and 2010 EPS estimate set at $0.19 and $0.60.
downgraded at Goldman from Buy to Neutral. $17 price target. Stock has almost doubled over the past two months.
downgraded at Goldman to Sell. Stock is already pricing in positive news from Brilinta and the company faces significant patent risk.
upgraded at FBR from Underperform to Market Perform. $134 price target. Valuation call, as consensus expectations have come down enough.
numbers raised at Goldman to $173. Estimates also increased, to reflect a lower share count, given management's commitment to buybacks. Neutral rating.
downgraded at Deutsche Bank. Rating lowered to Hold from Buy. Price target raised to $30.00 from $28.50. Maintains fiscal 2010 EPS estimates of $1.95.
upgraded at Citigroup from Hold to Buy. $16.50 price target. Selling by large shareholder has created a buying opportunity. Estimates also raised, to reflect higher commodity prices.
upgraded at Oppenheimer. Rating raised to Perform from Underperform. Price target raised to $37 from $27. Raises fiscal 2010 EPS estimates to $0.50 from $0.40.
downgraded at JP Morgan. Rating lowered to Neutral from Overweight. Price target raised to $85 from $80. Raises 2009 EPS estimates of $7.45 from $7.40.
rated new Neutral at Goldman. $17 price target. Company is mature, with fewer growth opportunities.
upgraded at Citigroup from Hold to Buy. $23 price target. Company has strong margin leverage and should benefit from robust handset trends.
upgraded at Merrill/BofA to Buy from Neutral on acceleration in billings and cash flow. Price target lifted to $29 from $23.50. 2010 and 2011 EPS estimates set at $0.67 and $0.72, respectively.
downgraded at Deutsche Bank. Rating lowered to Hold from Buy. Price target raised to $40 from $35. 2009 EPS estimates lowered to -$2.45 from -$1.85.
STOCK COMMENTS / EPS CHANGES
estimates lowered at UBS through 2010. Company will spend more on R&D for the Digeo acquisition, though core visibility is improving. Neutral rating and $13 price target.
Bed Bath & Beyond
price target lifted at Barclays to $35 from $32 on strong 2Q results. 2010 and 2011 EPS estimates increased to $1.90 from $1.78 and to $2.15 from $1.95, respectively. Reiterate Equal Weight rating.
estimates, target raised at Citigroup to $19. Estimates also boosted, to reflect increased price competition and slower sales in the U.S. Hold rating.
estimates, target boosted at Citigroup through 2012. Company should be able to sustain higher margins. Hold rating and new $28 price target.
added to Conviction Buy list at Goldman. $44 price target. Company has the potential for operating leverage as enterprise spending is expected to recover.
target boosted at Goldman to $17. Company has industry-low prices for its unsold homes. Buy rating.
cut from Top Picks list at Citigroup. $18 price target. Valuation call, as the stock is up 70% since late May. Buy rating.
numbers increased at Goldman. Shares now seen reaching $75. Estimates also boosted, to reflect higher realized margins. Neutral rating.
price target boosted at Merrill/BofA to $55 from $49 on growth opportunity for Crazy 8 stores. Reiterate Buy rating. 2010 and 2011 EPS estimates set at $3.21 and $3.63, respectively.
target boosted at Citigroup to $34. Company is gaining market share and its margins are holding up better than competitors. Buy rating.
estimates boosted at UBS through 2011. Company is focused on market share and cost-cutting. Buy rating and $28 price target.
estimates changed at Barclays. 2009 EPS estimates lowered to -$2.35 from -$2.34 and 2010 increased to $0.26 from $0.22. Maintain Equal Weight rating and $20 price target.
estimates, target boosted at Goldman. Shares of NKE now seen reaching $61. Estimates also raised, to reflect better foreign sales and the weaker dollar. Neutral rating.
numbers boosted at FBR. Shares now seen reaching $10.50. Recent checks show that business is tracking at the high end of expectations. Outperform rating.
price target raised at Merrill/BofA to $30 from $35 on signs that the trough in earnings is near. 2010 and 2011 EPS estimates set at $1.33 and $1.52, respectively. Reiterate Buy rating.
estimates, target increased at Goldman. Shares now seen reaching $25. Estimates also boosted, to reflect higher commodity prices and more demand from China. Neutral rating.
estimates, target boosted at UBS. Estimates were raised through 2011. Company boosted sales guidance, and operating leverage appears sustainable. Buy rating and new $27.50 price target.
price target higher at Merrill/BofA to $4.00 from $3.50 on improving economic data and the company's revised 2009 guidance, said Bank of America/Merrill Lynch. Maintain Buy rating. 2009 and 2010 EPS estimates set at -$0.25 and -$0.26, respectively.
This article was written by a staff member of TheStreet.com.